One hundred and forty patients were treated with weekly EndoTAG-1 ( 22 mg/m ( 2 ) ) plus paclitaxel ( 70 mg/m ( 2 ) ) , twice weekly EndoTAG-1 ( 2 44 mg/m ( 2 ) ) , or weekly paclitaxel ( 90 mg/m ( 2 ) ) for greater than or equal to four cycles ( 3-week treatment + 1-week rest ) or until progression/toxicity .